Lijun International Pharma Successfully Developed Enerxin Capsule, An Effective Restraint Of The Growth Of Influenza A (H1N1)

Published: Nov 09, 2009

Hong Kong, Nov 9, 2009 (ABN Newswire) - Lijun International Pharmaceutical (Holding) Co., Ltd. (HKG:2005) and its subsidiary (the "Group") are pleased to announce that Enerxin Capsule, which is developed and researched by Shijiazhuang No.4 Pharmaceutical Co., Ltd. ("Shijiazhuang No.4 Pharma"), a wholly-owned subsidiary of the Company, has been recognized by the State Key Laboratory of Virology for effective restraint of the growth of Influenza A (H1N1) on 31 October 2009.

Back to news